• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » goBalto, Informa partner on global site selection

goBalto, Informa partner on global site selection

June 16, 2017
CenterWatch Staff

goBalto, a provider of cloud-based clinical study startup (SSU) solutions, announced its partnership with Citeline, part of Informa's Pharma Intelligence vertical, to integrate data from Citeline's intelligence platforms—including Trialtrove and Sitetrove—with goBalto's Select. Indexing information captured by Citeline on more than 390,000 investigators across over 265,000 trials in more than 170 countries to the award-winning Select application aids in providing a data driven approach to weighing selection and performance variables in the identification of sites and target populations ideally suited to studies.

By incorporating data from Citeline into Select, mutual Citeline and goBalto clients can now easily and efficiently identify ideal sites at which to conduct their clinical trials.

Increased competition for sites and enrollment issues—determining whether specific sites have patients, combined with pressure to enroll patients quickly—has increased the number of non-active, non-enrolling (NANE) sites being activated for clinical trials. Combining all available data assets into one single view, increases the breadth of evidence available to encompass data from both public and private domains. This in turn enables both faster and better decision-making by considering all information in a single query as opposed to the current practice of running queries in multiple systems and having to consolidate results to understand the full landscape for the study.

This significant collaboration allows Citeline clients who subscribe to XML feeds and who are also clients of goBalto to access a broader range of data sources. By integrating key Citeline data components into Select's site identification, feasibility assessment and selection toolset, end-users can simplify the once arduous task of having to utilize multiple resources to research clinical trial investigators at high performing sites for their own clinical studies.

“We are excited to be working with goBalto for our mutual clients' benefit in accelerating clinical research. Our customers need an evidence-based site selection process with the ability to integrate data from multiple sources to drive further optimization efforts in the industry. Much of our strategy in 2017 revolves around adding value for our clients through strategic partnerships and we look forward to furthering the relationship with goBalto to assist our customers in achieving their goals,” said Jason Tse, head of Strategic Partnerships.

“By integrating data, both internal (e.g. CTMS, goBalto Activate performance metrics, etc.) and external (e.g., Citeline, PubMed, Clinicaltrials.gov, etc.), in one trusted location, we can now simplify the evidence-based planning and site identification process for our customers through access to a single integrated view of the data from all available sources,” said Sujay Jadhav, CEO, goBalto. “The Informa partnership is central to our customers’ efforts to streamline and automate the process of site identification in conjunction with data on performance experiences. We are committed to providing our customers with the functionality they need to accelerate the startup phases of clinical trials—and ultimately making valuable therapies available to patients sooner.”

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing